AN INNOVATIVE FORMULA …
To take full advantage of the virtues of turmeric, Tilman Laboratory has developed, in collaboration with a Belgian university center of research, bioactive extract of turmeric.
This extract, exclusive to Flexofytol®, is obtained by an unique formulation process that allows the curcumin to guarantee an optimal effect at a dosage of 42 mg. The bioactive curcumin contained in Flexofytol® has been scientifically studied on more than 2,800 Belgians and has shown that it helps to keep the joints supple1.
… AND SAFE
Unlike the regularly proposed alternatives in case of joint sensitivities, Flexofytol® can be used for long periods without gastric complications.
Moreover, its safety of use is also documented in Belgium2.
93% SATISFACTION! 3
Marketed since 2010, Flexofytol® has quickly become the reference product in Belgium for both doctors and pharmacists. Indeed, the Flexofytol® range is N°1 on the market but also the most prescribed product to help keep joints and tendons supple4!
HOW TO USE
JOINTS
Initial intake
| From 6 to 12 years | 2 capsules in the morning during 1 month. |
| Older than 12 years | 2 capsules in the morning and in the evening during 1 month. |
Maintenance
| From 6 to 12 years | 1 capsule in the morning. |
| Older than 12 years | 2 capsules in the morning. |
TENDONS
| From 6 to 12 years | 2 capsules in the morning and in the evening during 1 week. |
| Older than 12 years | 4 capsules in the morning and in the evening during 1 week. |
Flexofytol® can’t be used for children under 6 years old.
PRECAUTIONS OF USE
- Do not use during pregnancy and breastfeeding.
- Stop using this product in case of persistent diarrhea.
- Medical supervision if anticoagulants are being used simultaneously.
EXISTS IN 2 FORMATS
Box of 60 capsules
20,90€ (CNK=2663-615)
Box of 180 capsules
56,40€ (CNK=2663-623)
1 Henrotin et al. Arthritis Research & Therapy volume 21, Article number: 179 (2019)
2 De Breucker et al. Open Journal of Rheumatology and Autoimmune Diseases, 2017, 7, 167-177.
3 Henrotin et al. SpringerPlus 2013, 2-56
4 Source IMS juin 2020 – Market OTC Joint care prds (systemic)
This post is also available in: Belgique-FR België-NL Français-FR
